Company Information

SUVEN PHARMACEUTICALS LTD.

NSE : SUVENPHARBSE : 543064ISIN CODE : INE03QK01018Industry : Pharmaceuticals & DrugsHouse : Private
BSE671.201.7 (+0.25 %)
PREV CLOSE ( ) 669.50
OPEN PRICE ( ) 670.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1762
TODAY'S LOW / HIGH ( )658.50 674.55
52 WK LOW / HIGH ( )427.05 767
NSE672.102.5 (+0.37 %)
PREV CLOSE( ) 669.60
OPEN PRICE ( ) 670.00
BID PRICE (QTY) 672.10 (5)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 157209
TODAY'S LOW / HIGH( ) 657.00 674.90
52 WK LOW / HIGH ( )469.45 768
ChairmanAnnaswamy Vaidheesh
Managing DirectorV Prasada Raju
Company SecretaryK Hanumantha Rao
Non Executive Independent DirectorMatangi Gowrishankar
Vinod Rao
KG Ananthakrishnan
Pravin Rao
Non Independent & Non Executive DirectorPankaj Patwari
Shweta Jalan
Incorporation Year : 06-11 2018

Registered Office :

Address : 215 Atrium, C Wing, 8th Floor, 819-821,Andheri, Kurla Road, Chakala,Andheri East, Chakala Midc Mumbai,
Maharashtra-400093 .

Phone : 040 - 2354 9414 / 1142 /3311

Email :  info@suvenpharm.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.